Daclatasvir

Results: 9



#Item
1State of Illinois Illinois Department of Public Health Ryan White Part B ADAP Medication Assistance Program (MAP) Application for Pre Approval of Hepatitis C Medication Assistance The following medications are n o w avai

State of Illinois Illinois Department of Public Health Ryan White Part B ADAP Medication Assistance Program (MAP) Application for Pre Approval of Hepatitis C Medication Assistance The following medications are n o w avai

Add to Reading List

Source URL: hivcareconnect.com

Language: English - Date: 2016-05-03 16:46:58
2NLT-gruppens yttrande till landstingen gällande nya läkemedel vid kronisk hepatit C: simeprevir (Olysio) sofosbuvir (Sovaldi) och daclatasvir (Daklinza) samt kommentar kring ledipasvir/sofosbuvir (Harvoni)

NLT-gruppens yttrande till landstingen gällande nya läkemedel vid kronisk hepatit C: simeprevir (Olysio) sofosbuvir (Sovaldi) och daclatasvir (Daklinza) samt kommentar kring ledipasvir/sofosbuvir (Harvoni)

Add to Reading List

Source URL: www.janusinfo.se

Language: Swedish - Date: 2014-12-22 02:37:28
    3ANRS HC 32 QUATTRO Etude pilote évaluant l’efficacité et la tolérance d’une QUADRITHERAPIE associant Asunaprevir, Daclatasvir, Ribavirine et Peginterféron alpha-2a chez les patients infectés par le VHC de génot

    ANRS HC 32 QUATTRO Etude pilote évaluant l’efficacité et la tolérance d’une QUADRITHERAPIE associant Asunaprevir, Daclatasvir, Ribavirine et Peginterféron alpha-2a chez les patients infectés par le VHC de génot

    Add to Reading List

    Source URL: www.anrs.fr

    Language: French - Date: 2014-12-15 08:45:11
      4New drug could eliminate hepatitis C in 15 years The Pharmaceutical Journal, 10 SEP 2014, By Janna Lawrence Daclatasvir is estimated to cure chronic hepatitis C infection in up to 99% of cases when used in combination wi

      New drug could eliminate hepatitis C in 15 years The Pharmaceutical Journal, 10 SEP 2014, By Janna Lawrence Daclatasvir is estimated to cure chronic hepatitis C infection in up to 99% of cases when used in combination wi

      Add to Reading List

      Source URL: www.hepcassoc.org

      Language: English - Date: 2014-09-15 11:42:23
      5ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Daclatasvir+sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% of

      ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Daclatasvir+sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% of

      Add to Reading List

      Source URL: www.hepcassoc.org

      Language: English - Date: 2014-11-10 11:48:39
      6Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis Daclatasvir TRIO achieves 98% cure

      Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis Daclatasvir TRIO achieves 98% cure

      Add to Reading List

      Source URL: www.hepcassoc.org

      Language: English - Date: 2014-11-10 11:48:36
      7Drugs in Development: Phase 3, Genotype 1b: BMS’s Daclatasvir Plus Asunaprevir Combination

      Drugs in Development: Phase 3, Genotype 1b: BMS’s Daclatasvir Plus Asunaprevir Combination

      Add to Reading List

      Source URL: www.hcvadvocate.org

      Language: English - Date: 2014-09-18 02:13:21
      8Drugs in Development: Phase 3, Genotype 1: BMS’s Daclatasvir Plus Sofosbuvir Combination

      Drugs in Development: Phase 3, Genotype 1: BMS’s Daclatasvir Plus Sofosbuvir Combination

      Add to Reading List

      Source URL: www.hcvadvocate.org

      Language: English - Date: 2014-09-18 02:13:23
      9Drugs in Development: Phase 3, Genotype 2 & 3: BMS’s Daclatasvir Plus Sofosbuvir Combination

      Drugs in Development: Phase 3, Genotype 2 & 3: BMS’s Daclatasvir Plus Sofosbuvir Combination

      Add to Reading List

      Source URL: www.hcvadvocate.org

      Language: English - Date: 2014-09-18 02:13:25